Redx Pharma plc Redx Appoints Senior AstraZeneca Executive as CEO (8499L)
24 April 2018 - 4:01PM
UK Regulatory
TIDMREDX
RNS Number : 8499L
Redx Pharma plc
24 April 2018
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF
THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
REDX PHARMA PLC
("Redx" or "the Company")
Redx appoints Senior AstraZeneca Executive as new Chief
Executive Officer
Alderley Park, 24 April 2018 Redx (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
announces that it has appointed Lisa Anson as Chief Executive
Officer (CEO) and to its Board of Directors. Lisa will take up both
roles on 1 June 2018. At that time Iain Ross, currently Executive
Chairman, will revert to being Non-Executive Chairman.
Lisa Anson, aged 49, has been President of AstraZeneca UK since
2012 and brings significant leadership experience to the role. Over
a 20 year career with AstraZeneca, Lisa has held a variety of
senior management roles at AstraZeneca in both the US and the UK
including Global Vice President Oncology and Vice President of
Emerging Brands working closely with the Research and Development
teams.
Lisa holds a MBA (awarded with distinction) from INSEAD, France
and a First Class honours degree in Natural Sciences from Cambridge
University. Upon graduating she joined KPMG in London as a
management consultant and then moved to California where she worked
for Salick Health Care (now Aptium), a cancer disease management
company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a
business development manager.
Lisa is the current President of the Association of the British
Pharmaceutical Industry (ABPI).
Iain Ross, Executive Chairman of Redx plc, said:
"On behalf of the Board and the team, I welcome Lisa to Redx.
Following the events of 2017 Lisa has been tasked by the Board to
lead the re-launch of the Company and to take the steps necessary
to build a substantial biotech company built upon an innovative
science base, selectively acquiring additional assets, if
appropriate. Lisa is a consummate business professional, who brings
a wealth of relevant experience from the international
pharmaceutical and biotech sector. I am confident that, as CEO, she
is the right person to grow this Company into a very exciting and
meaningful entity that has the potential to create both important
new medicines for patients and generate significant value for
shareholders."
"I would like to take this opportunity to thank the Redx team
for the tremendous effort they have made over the last six months
whilst the business has been in transition. Lisa's appointment
marks a new beginning"
Lisa Anson, CEO designate of Redx plc, added:
"I am incredibly excited by the opportunity to lead Redx on the
next stage of its journey to be a leading UK Biotech company. The
team have impressed me and The Company now has a clear focus on
some very exciting areas of science in both fibrosis and cancer
where there are a number of ongoing programmes. I look forward to
working with the team and the Board to build and develop Redx to
its full potential"
Additional Information
The following information is being disclosed pursuant to Rule 17
and paragraph (g) of Schedule 2 of the AIM Rules for Companies.
Full name: Lisa Mary Whewell Anson
Ms Anson does not hold any shares in the Company.
Ms Anson is a director of the Association of the British
Pharmaceutical Industry, the Office for Health Economics and a
trustee for Wilmslow Preparatory School. Ms Anson was previously a
director of Weston Sports & Media LLP and Weston Sports &
Media Consulting Limited.
-Ends-
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on
AIM (AIM:REDX). Redx is focused on creating and developing first,
or potentially best in class drugs, in specific areas of cancer and
fibrosis that address significant unmet medical need. Redx has an
in-house discovery team with proven world-class chemistry
capabilities.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFFASTIVFIT
(END) Dow Jones Newswires
April 24, 2018 02:01 ET (06:01 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024